GU Oncology Now
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.
The Road Ahead: Molecular Profiling, Novel Agents, and Quality-of-Life Considerations
Access, Tolerability, and Trial Limitations: Practical Decision-Making in CRPC
Evolving Standards: Triplet Therapy and the Role of Bone-Directed Agents
Therapy Buckets in Practice: Personalizing Treatment Pathways in Advanced Prostate Cancer
Identifying High-Risk Patients: Predictors of Progression to CRPC
From Tumor Boards to Trials: Evolving Approaches in Oligometastatic Prostate Cancer
Upfront Testing and Monitoring: Practical Approaches in Metastatic Prostate Cancer
Next Steps for EV/Pembro: Toxicity Management, ctDNA, and Emerging Trials
When to Scale Back: Insights from an Ongoing EV/Pembro De-Escalation Pilot Study
De-Escalation Strategies with EV/Pembro: Clinical Rationale and Evidence
Looking Ahead: Gaps, Hurdles, and Transition in Current Phase 2 RLT Trial Landscape
Key Trends in Ongoing Phase 2 RLT Trials
Expanding the Reach: TAR-200 in Papillary Disease and Beyond
Combination Therapy in SunRISe-1: Lessons from Cetrelimab and TAR-200
Primary vs Nodal Response: What Discordance Means for Surgical Planning
Robotic vs Open Cytoreductive Cystectomy: Lessons from Early Experience
Stopping Systemic Therapy: When Surgery Enables a Treatment Holiday
Cytoreductive Cystectomy After EV-302: How We Got Here
HRD Signatures, PARP, and Radiation: Where Science Meets Practice
Emerging Frontiers: T-Cell Engagers, Radioligands, and BCR
Balancing ARPI Use, PSA Response, and Genomics in Treatment Planning
Radium-223 vs Pluvicto: Evolving Roles in Bone-Predominant mCRPC
Choosing the Right ARPI: Clinical and Practical Considerations
High-Volume Disease in the PSMA-PET Era: Trials, Imaging, and Real-World Decisions
Upfront Treatment Strategies for De Novo Metastatic Prostate Cancer
Advancing Therapies for Chromophobe RCC: KIT as a Gateway for Targeted Drug Delivery
The Future of NMIBC Treatment: Going Beyond the Standard of Care Through Shared Decision Making
ENVISION Trial Update: Integrating a New Treatment into NMIBC Standard of Care
Redefining Treatment in Intermediate-Risk NMIBC: Navigating an Evolving Landscape
Perioperative Advances and ctDNA: The Next Frontier in Metastatic Bladder Cancer